Olema Pharmaceuticals, Inc.
OLMANASDAQHealthcare● Active
$10.50
+$0.54(+5.42%)
Market Cap$917148446
P/E Ratio—
52W High$36.259
52W Low$3.89
Olema Pharmaceuticals, Inc. (OLMA) · Cash Flow
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · OLMA · as of 2026-06-10
Financial statements
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | ($0.16B) | ($0.13B) | ($0.10B) | ($0.10B) | ($0.07B) |
| Depreciation & Amort. | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Stock-Based Comp. | $0.02B | $0.02B | $0.02B | $0.00B | $0.00B |
| Change in Working Capital | $0.00B | $0.01B | ($0.00B) | $0.00B | $0.00B |
| Net Cash from Operations | ($0.15B) | ($0.10B) | ($0.08B) | ($0.08B) | ($0.05B) |
| Investing Activities | |||||
| Capital Expenditure | $0.00B | ($0.00B) | $0.00B | ($0.00B) | ($0.00B) |
| Purchases of Investments | ($0.50B) | ($0.39B) | ($0.26B) | ($0.21B) | ($0.49B) |
| Sales of Investments | $0.34B | $0.30B | $0.25B | $0.31B | $0.21B |
| Net Cash from Investing | ($0.16B) | ($0.09B) | ($0.00B) | $0.09B | ($0.28B) |
| Financing Activities | |||||
| Common Stock Repurchased | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Dividends Paid | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Debt Issued / Repaid | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Net Cash from Financing | $0.21B | $0.27B | $0.13B | $0.00B | $0.00B |
| Free Cash Flow | |||||
| Free Cash Flow | ($0.15B) | ($0.10B) | ($0.08B) | ($0.08B) | ($0.05B) |
| FCF Margin %(computed) | — | — | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-10 · USD · B
Explore more Olema Pharmaceuticals, Inc. data
About Olema Pharmaceuticals, Inc. (OLMA) Cash Flow Statement
Olema Pharmaceuticals, Inc. generated operating cash flow of ($0.15B) and free cash flow of ($0.15B) for 2025 — a FCF margin of —. Capital expenditure was $0.00B.
Frequently asked questions
OLMA · 4 questionsOlema Pharmaceuticals, Inc. generated free cash flow of ($0.15B) for 2025, down 40.4% year-over-year.
OLMA free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10